Skip to content

Study · Ex vivo tissue · cat · 1991

2 results

Effects of vasoactive intestinal polypeptide antagonists on cholinergic neurotransmission in dog and cat trachea.

Xie ZQ, Hirose T, Hakoda H, Ito Y

British journal of pharmacology1 Dec 1991Cited by 8 (Europe PMC)

PMID1667294 (opens in a new tab)PMCIDPMC1908857 (opens in a new tab)DOI10.1111/j.1476-5381.1991.tb12530.x (opens in a new tab)PepBankPUB-01667294
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueMechanism

    In cat trachea, VIP suppressed the amplitude of excitatory junction potentials to 0.74 times the control value.

    In plain wordsIn cat windpipe tissue, VIP reduced the size of nerve-driven muscle signals to about three quarters of the control.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseExcitatory junction potential amplitude with VIP
    Study

    catn = 6

    Cat trachea smooth muscle
    Outcome group
    Receptor activity and mechanism · Respiratory
    Studied dose
    10-11 MAs given in this study (cat).

    Measurements

    Relative ejp amplitude
    0.74 x control
    cat trachea, VIP 10-11 M

    Source sentences

    Summary
    In the cat trachea, VIP (10-11 M) suppressed the ej.p. amplitude to 0.74 +/- 0.09 times the control value (n = 6).

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism

    In cat trachea pretreated with VIP antagonists, VIP no longer suppressed the excitatory junction potential amplitude.

    In plain wordsIn cat windpipe tissue, VIP-blocking compounds stopped VIP from reducing nerve-driven muscle signals.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP suppression of excitatory junction potential after antagonist pretreatment
    Study

    catn: not reported in source

    Cat trachea smooth muscle
    Outcome group
    Receptor activity and mechanism · Respiratory

    Source sentences

    Summary
    However, after pretreatment of the tissue with the VIP antagonists [Ac-Tyr', D-Phe2]-GRF(1-29)- H2 (10-8M) and [4-Cl-D-Phe6, Leu17]-VIP (10-8M), VIP (10-11 M) did not suppress the ej.p. amplitude

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 12:41 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.